NRx Prescribed drugs, Inc. (NASDAQ:NRXP) will launch earnings for its first quarter earlier than the opening bell on Monday, Might 18.
Analysts anticipate the Wilmington, Delaware-based firm to report quarterly lack of 11 cents per share, versus a lack of 34 cents per share within the year-ago interval. The consensus estimate for NRx Prescribed drugs’ quarterly income is $19.43 million, in keeping with Benzinga Professional.
On Might 7, NRx Pharma obtained clearance from the FDA to provoke medical trial of NRX-101 vs. placebo in sufferers with melancholy and suicidality.
NRx Prescribed drugs shares gained 8.8% to shut at $3.21 on Thursday.
Benzinga readers can entry the newest analyst scores on the Analyst Inventory Rankings web page. Readers can kind by inventory ticker, firm identify, analyst agency, ranking change or different variables.
Let’s take a look at how Benzinga’s most-accurate analysts have rated the corporate within the current interval.
Contemplating shopping for NRXP inventory? Right here’s what analysts suppose:
Photograph by way of Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
So as to add Benzinga Information as your most well-liked supply on Google, click on right here.
